Stock abbreviation: Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) Stock Code: Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) Announcement No.: Lin 2022052
Bond abbreviation: Huahai convertible bond bond Code: 110076
Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521)
Announcement on the progress of repurchasing the company’s shares by means of centralized bidding transaction
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Implementation of repurchase plan: as of April 30, 2022, the company has repurchased the company’s shares accumulatively
8561008 shares, accounting for 0.5739% of the total share capital of the company. The highest transaction price is 21.76 yuan / share, the lowest price is 14.77 yuan / share, and the total transaction amount is 16636698460 yuan (excluding stamp duty, transaction commission and other related expenses). 1、 Basic information of repurchase
Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) (hereinafter referred to as “the company”) held the second meeting of the seventh board of directors and the 2020 annual general meeting of shareholders on April 23, 2021 and May 18, 2021 respectively. The meeting deliberated and approved the proposal on repurchase of shares of the company by centralized bidding transaction, and agreed that the company would use its own funds to repurchase shares of the company by centralized bidding transaction for the implementation of employee stock ownership plan or equity incentive, The repurchase amount shall not be less than 100 million yuan (inclusive) and not more than 200 million yuan (inclusive), and the repurchase price shall not exceed 24.80 yuan / share (inclusive) (the company originally set the upper limit of repurchase price to be 25 yuan / share. Because the company implemented the 2020 annual profit distribution plan, that is, the company distributed cash bonus of 0.2 yuan per share (inclusive of tax), the company adjusted the upper limit of repurchase price according to the provisions of relevant laws and regulations, Adjusted from 25 yuan / share to 24.80 yuan / share), the repurchase period is within 12 months from the date when the company’s 2020 annual general meeting deliberates and approves the share repurchase plan.
For details, please refer to China Securities Journal, Shanghai Securities News, securities times, securities daily and the website of Shanghai Stock Exchange on April 26, 2021, May 19, 2021 and June 12, 2021 com. cn. Announcement of Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) on share repurchase scheme through centralized bidding transaction (p.2021028), announcement of Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) 2020 annual general meeting resolution (p.2021040), announcement of Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) on adjusting the upper limit of share repurchase price (p.2021056).
2、 Progress of repurchase
In April 2022, the Company repurchased 50000 shares of the company through centralized bidding transaction. The proportion of repurchased shares in the total share capital of the company was 0.0034%, the transaction price was 14.77 yuan / share, and the total transaction amount was 73850000 yuan (excluding stamp duty, transaction commission and other related expenses).
As of April 30, 2022, the company has repurchased 8561008 shares, accounting for 0.5739% of the total share capital of the company. The highest transaction price is 21.76 yuan / share, the lowest price is 14.77 yuan / share, and the total transaction amount is 16636698460 yuan (excluding stamp duty, transaction commission and other related expenses).
3、 Other instructions
Subsequently, the company will implement the repurchase plan within the repurchase period in accordance with the requirements of normative documents such as the rules for share repurchase of listed companies and market conditions, and timely perform the obligation of information disclosure in accordance with the requirements of relevant normative documents. Please pay attention to investment risks.
It is hereby announced.
Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) board of directors
May 4, 2022
